Literature DB >> 35173151

Differential V2-directed antibody responses in non-human primates infected with SHIVs or immunized with diverse HIV vaccines.

Svenja Weiss1, Vincenza Itri1, Ruimin Pan2, Xunqing Jiang2, Christina C Luo2, Lynn Morris3,4, Delphine C Malherbe5,6, Philip Barnette5, Jeff Alexander7,8, Xiang-Peng Kong2, Nancy L Haigwood5, Ann J Hessell5, Ralf Duerr9, Susan Zolla-Pazner10,11.   

Abstract

V2p and V2i antibodies (Abs) that are specific for epitopes in the V1V2 region of the HIV gp120 envelope (Env) do not effectively neutralize HIV but mediate Fc-dependent anti-viral activities that have been correlated with protection from, or control of HIV, SIV and SHIV infections. Here, we describe a novel molecular toolbox that allows the discrimination of antigenically and functionally distinct polyclonal V2 Ab responses. We identify different patterns of V2 Ab induction by SHIV infection and three separate vaccine regimens that aid in fine-tuning an optimized immunization protocol for inducing V2p and V2i Abs. We observe no, or weak and sporadic V2p and V2i Abs in non-vaccinated SHIV-infected NHPs, but strong V2p and/or V2i Ab responses after immunization with a V2-targeting vaccine protocol. The V2-focused vaccination is superior to both natural infection and to immunization with whole Env constructs for inducing functional V2p- and V2i-specific responses. Strikingly, levels of V2-directed Abs correlate inversely with Abs specific for peptides of V3 and C5. These data demonstrate that a V1V2-targeting vaccine has advantages over the imprecise targeting of SIV/SHIV infections and of whole Env-based immunization regimens for inducing a more focused functional V2p- and V2i-specific Ab response.
© 2022. The Author(s).

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35173151      PMCID: PMC8850611          DOI: 10.1038/s41467-022-28450-1

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  94 in total

1.  Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.

Authors:  Susan Zolla-Pazner; Rebecca Powell; Sara Yahyaei; Constance Williams; Xunqing Jiang; Wei Li; Shan Lu; Shixia Wang; Chitra Upadhyay; Catarina E Hioe; Max Totrov; Xiangpeng Kong
Journal:  J Virol       Date:  2016-11-28       Impact factor: 5.103

2.  Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection.

Authors:  Timothy R Fouts; Kenneth Bagley; Ilia J Prado; Kathryn L Bobb; Jennifer A Schwartz; Rong Xu; Robert J Zagursky; Michael A Egan; John H Eldridge; Celia C LaBranche; David C Montefiori; Hélène Le Buanec; Daniel Zagury; Ranajit Pal; George N Pavlakis; Barbara K Felber; Genoveffa Franchini; Shari Gordon; Monica Vaccari; George K Lewis; Anthony L DeVico; Robert C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-13       Impact factor: 11.205

3.  Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles.

Authors:  Miroslaw K Gorny; Leonidas Stamatatos; Barbara Volsky; Kathy Revesz; Constance Williams; Xiao-Hong Wang; Sandra Cohen; Robert Staudinger; Susan Zolla-Pazner
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

4.  HIV/SIV DNA vaccine combined with protein in a co-immunization protocol elicits highest humoral responses to envelope in mice and macaques.

Authors:  Jinyao Li; Antonio Valentin; Viraj Kulkarni; Margherita Rosati; Rachel Kelly Beach; Candido Alicea; Drew Hannaman; Steven G Reed; Barbara K Felber; George N Pavlakis
Journal:  Vaccine       Date:  2013-04-26       Impact factor: 3.641

5.  Distinct mechanisms regulate exposure of neutralizing epitopes in the V2 and V3 loops of HIV-1 envelope.

Authors:  Chitra Upadhyay; Luzia M Mayr; Jing Zhang; Rajnish Kumar; Miroslaw K Gorny; Arthur Nádas; Susan Zolla-Pazner; Catarina E Hioe
Journal:  J Virol       Date:  2014-08-27       Impact factor: 5.103

6.  Liposome-Encapsulated Human Immunodeficiency Virus-1 gp120 Induces Potent V1V2-Specific Antibodies in Humans.

Authors:  Mangala Rao; Sayali Onkar; Kristina K Peachman; Yohann White; Hung V Trinh; Ousman Jobe; Yingjun Zhou; Peter Dawson; Michael A Eller; Gary R Matyas; Carl R Alving
Journal:  J Infect Dis       Date:  2018-10-05       Impact factor: 5.226

7.  Anti-V2 antibody deficiency in individuals infected with HIV-1 in Cameroon.

Authors:  Lily Liu; Liuzhe Li; Aubin Nanfack; Luzia M Mayr; Sonal Soni; Adam Kohutnicki; Lucy Agyingi; Xiao-Hong Wang; Michael Tuen; Yongzhao Shao; Maxim Totrov; Susan Zolla-Pazner; Xian-Peng Kong; Ralf Duerr; Miroslaw K Gorny
Journal:  Virology       Date:  2019-01-14       Impact factor: 3.616

8.  A Broadly Neutralizing Antibody Targets the Dynamic HIV Envelope Trimer Apex via a Long, Rigidified, and Anionic β-Hairpin Structure.

Authors:  Jeong Hyun Lee; Raiees Andrabi; Ching-Yao Su; Anila Yasmeen; Jean-Philippe Julien; Leopold Kong; Nicholas C Wu; Ryan McBride; Devin Sok; Matthias Pauthner; Christopher A Cottrell; Travis Nieusma; Claudia Blattner; James C Paulson; Per Johan Klasse; Ian A Wilson; Dennis R Burton; Andrew B Ward
Journal:  Immunity       Date:  2017-04-18       Impact factor: 31.745

9.  Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in Adults.

Authors:  Glenda E Gray; Linda-Gail Bekker; Fatima Laher; Mookho Malahleha; Mary Allen; Zoe Moodie; Nicole Grunenberg; Yunda Huang; Doug Grove; Brittany Prigmore; Jia J Kee; David Benkeser; John Hural; Craig Innes; Erica Lazarus; Graeme Meintjes; Nivashnee Naicker; Dishiki Kalonji; Maphoshane Nchabeleng; Modulakgotla Sebe; Nishanta Singh; Philip Kotze; Sheetal Kassim; Thozama Dubula; Vimla Naicker; William Brumskine; Cleon N Ncayiya; Amy M Ward; Nigel Garrett; Girisha Kistnasami; Zakir Gaffoor; Pearl Selepe; Philisiwe B Makhoba; Matsontso P Mathebula; Pamela Mda; Tania Adonis; Katlego S Mapetla; Bontle Modibedi; Tricia Philip; Gladys Kobane; Carter Bentley; Shelly Ramirez; Simbarashe Takuva; Megan Jones; Mpho Sikhosana; Millicent Atujuna; Michele Andrasik; Nima S Hejazi; Adrian Puren; Lubbe Wiesner; Sanjay Phogat; Carlos Diaz Granados; Marguerite Koutsoukos; Olivier Van Der Meeren; Susan W Barnett; Niranjan Kanesa-Thasan; James G Kublin; M Juliana McElrath; Peter B Gilbert; Holly Janes; Lawrence Corey
Journal:  N Engl J Med       Date:  2021-03-25       Impact factor: 91.245

10.  Priming with DNA Expressing Trimeric HIV V1V2 Alters the Immune Hierarchy Favoring the Development of V2-Specific Antibodies in Rhesus Macaques.

Authors:  Santhi Devasundaram; Margherita Rosati; Antonio Valentin; Svenja Weiss; Vincenza Itri; Hung V Trinh; Jenifer Bear; Bhabadeb Chowdhury; Celia C LaBranche; David Montefiori; Guido Ferrari; Mangala Rao; Xiang-Peng Kong; Susan Zolla-Pazner; George N Pavlakis; Barbara K Felber
Journal:  J Virol       Date:  2020-12-22       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.